This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Patten, S. B Articles by Curtin, F. Search for Related Content PubMed PubMed Citation Articles by Patten, S. B Articles by Curtin, F. Social Bookmarking                   What's this?

The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis

Department of Community Health Sciences and Psychiatry, University of Calgary, Calgary, Alberta, Canada, patten{at}ucalgary.ca

Gordon Francis

Neurology Global Product Development, Serono Inc. Rockland, MA, USA and Geneva, Switzerland

Luanne M Metz

Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada

Maria Lopez-Bresnahan

Neurology Global Product Development, Serono Inc. Rockland, MA, USA and Geneva, Switzerland

Peter Chang

Biostatistics, Serono Inc. Rockland, MA, USA and Geneva, Switzerland

Francois Curtin

Pharmacovigilance, Serono Inc. Rockland, MA, USA and Geneva, Switzerland

It has been suggested that interferons (IFN) may cause depressionde novo or worsen pre-existing depression. Depression data collected using validated instruments from individual clinical trials in multiple sclerosis, however, have consistently failed to identify an association. In this study, pooled data from 6 controlled studies and 17 noncontrolled clinical trials of subcutaneous IFN beta-1a were assessed to determine the relationship between IFN therapy with physician reports of depression and suicide. In distinction to the negative findings for depressive symptom ratings, pooling of physician-reported side effect data from these clinical trials identified a statistically significant association between depression and IFN use during the first six months of treatment. There was an association between these reported episodes of depression and discontinuation of IFN therapy, but IFN treatment was not associated with suicide attempts. IFN ß-1a may induce a constellation of symptoms, particularly early in therapy, that may be labelled as depression by physicians. However, the lack of an increase in depression-rating scale scores and the lack of association with suicide risk suggests that the syndrome may be an atypical one.

Key Words: adverse effects • chemically induced depressive disorder • depressive symptoms • interferons • mental depression • multiple sclerosis • post marketing • product surveillance • psychiatric symptom rating scales

Multiple Sclerosis, Vol. 11, No. 2, 175-181 (2005)
DOI: 10.1191/1352458505ms1144oa


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. Patten, J. Williams, and L. Metz Anti-depressant use in association with interferon and glatiramer acetate treatment in multiple sclerosis Multiple Sclerosis, April 1, 2008; 14(3): 406 - 411. [Abstract] [PDF]